Decoy Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(4,598,428) | $(2,667,358) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 19,556 | 2,212 |
| Equity-based compensation | 419,221 | 56,689 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (272,847) | (11,659) |
| Accounts payable | (235,170) | 337,971 |
| Accrued expenses and other | (646,051) | 238,134 |
| Deferred revenue | (227,629) | — |
| Net cash used in operating activities | (5,541,348) | (2,044,011) |
| Investing activities | ||
| Purchase of fixed assets | (42,424) | — |
| Net cash used in investing activities | (42,424) | — |
| Financing activities | ||
| Proceeds from issuance of equity securities, net | 3,162,943 | 626,235 |
| Payments on note payable | — | (221,866) |
| Net cash provided by financing activities | 3,162,943 | 404,369 |
| Net decrease in cash | (2,420,829) | (1,639,642) |
| Cash, cash equivalents, and restricted cash at beginning of period | 10,709,937 | 2,434,528 |
| Cash, cash equivalents, and restricted cash at end of period | $8,289,108 | $794,886 |
| Supplemental cash flow information | ||
| Cash paid for interest | $— | $5,800 |
| Accrued issuance costs for public offering | $551,799 | $356,984 |
| Property and equipment purchases in accounts payable | $69,567 | $— |
| Property and equipment reclassified from prepaid expenses | $263,870 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.